Skip to main navigation
  • Investors
    • Press Releases
    • Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
    • Scientific Publications & Presentations
  • Newsroom
  • Medical Professionals
  • Careers
    • Intern Program
    • Postdoctoral Program
  • Contact Us
Ionis Pharmaceuticals, Inc. home page

Main navigation

  • About Us
    • Our Leadership
    • Our Culture
    • Corporate Responsibility
    • Grants & Sponsorships
  • Areas of Focus
  • Science & Innovation
    • Pipeline
    • Clinical Trials
    • Ion-ARPA Initiative
  • Medicines
  • Patients & Advocacy
    • Patient Stories
    • Patient Resources
    • Expanded Access Policy
Media Center

Investor Relations

  • Overview
  • Investor News
    • Press Releases
    • Company Statements
    • Media Kit
  • Events
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
    • Ownership Profile
  • Financials
    • SEC Filings
    • Annual Reports
  • Governance
    • Governance Documents
    • Committee Composition
  • Investor Resources
    • Investor FAQs
    • Settlement Information
    • Contact Us
  • Scientific Publications & Presentations
  • Investor Email Alerts

Investor contact

760-603-2331

Email

Media contact

760-603-4679

Email

Event Details

TRYNGOLZAᵀᴹ (olezarsen) FDA approval Webcast

Dec 19, 2024 6:45 PM EST

Listen to webcast

Supporting Materials

View Presentation 2 MB

Footer Navigation

  • Legal and Compliance:
    • Legal Notice
    • Code of Ethics and Business Conduct
    • Privacy Policy
    • Consumer Health Data Privacy Policy
    • Your Privacy Choices
    • Akcea Therapeutics
  • Information For:
    • Medical Professionals
    • Investors & Media
    • Job Seekers
    • Suppliers
  • Explore:
    • Our Story
    • Our Science
    • Our Pipeline
    • Our Culture
    • Our News
  • Stay Connected:
    • Contact Us
    • LinkedIn
    • X
    • Instagram
    • Facebook
    • Community Guidelines

©1989 – 2026 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
Akcea Therapeutics® is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. logo